Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 138

1.

Targeting Angiogenic Pathways in Colorectal Cancer: Complexities, Challenges and Future Directions.

Khan K, Cunningham D, Chau I.

Curr Drug Targets. 2015 Mar 25. [Epub ahead of print]

PMID:
25808652
2.

Pancreatic neuroendocrine tumors: a review.

Young K, Iyer R, Morganstein D, Chau I, Cunningham D, Starling N.

Future Oncol. 2015 Mar;11(5):853-64. doi: 10.2217/fon.14.285.

PMID:
25757686
3.

The role of routine clinical pretreatment 18F-FDG PET/CT in predicting outcome of colorectal liver metastasis.

Tam HH, Cook GJ, Chau I, Drake B, Zerizer I, Du Y, Cunningham D, Koh DM, Chua SS.

Clin Nucl Med. 2015 May;40(5):e259-64. doi: 10.1097/RLU.0000000000000744.

PMID:
25742225
4.

Circulating Tumor Cell Enumeration in a Phase II Trial of a Four-Drug Regimen in Advanced Colorectal Cancer.

Krebs MG, Renehan AG, Backen A, Gollins S, Chau I, Hasan J, Valle JW, Morris K, Beech J, Ashcroft L, Saunders MP, Dive C.

Clin Colorectal Cancer. 2015 Jun;14(2):115-122.e2. doi: 10.1016/j.clcc.2014.12.006. Epub 2014 Dec 31.

PMID:
25680623
5.

The effect of a primary tumour resection on the progression of synchronous colorectal liver metastases: an exploratory study.

Slesser AA, Khan F, Chau I, Khan AZ, Mudan S, Tekkis PP, Brown G, Rao S.

Eur J Surg Oncol. 2015 Apr;41(4):484-92. doi: 10.1016/j.ejso.2014.12.009. Epub 2015 Jan 17.

PMID:
25638603
6.

Prognostic factors and treatment outcomes in patients with Small Bowel Adenocarcinoma (SBA): The Royal Marsden Hospital (RMH) experience.

Khan K, Peckitt C, Sclafani F, Watkins D, Rao S, Starling N, Jain V, Trivedi S, Stanway S, Cunningham D, Chau I.

BMC Cancer. 2015 Jan 21;15:15. doi: 10.1186/s12885-015-1014-6.

7.

Phase I study of olaparib plus gemcitabine in patients with advanced solid tumours and comparison with gemcitabine alone in patients with locally advanced/metastatic pancreatic cancer.

Bendell J, O'Reilly EM, Middleton MR, Chau I, Hochster H, Fielding A, Burke W, Burris H 3rd.

Ann Oncol. 2015 Apr;26(4):804-11. doi: 10.1093/annonc/mdu581. Epub 2015 Jan 7.

PMID:
25573533
8.

Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trial.

Gruenberger T, Bridgewater J, Chau I, García Alfonso P, Rivoire M, Mudan S, Lasserre S, Hermann F, Waterkamp D, Adam R.

Ann Oncol. 2015 Apr;26(4):702-8. doi: 10.1093/annonc/mdu580. Epub 2014 Dec 23.

PMID:
25538173
9.

Ramucirumab: targeting angiogenesis in the treatment of gastric cancer.

Smyth EC, Tarazona N, Chau I.

Immunotherapy. 2014;6(11):1177-86. doi: 10.2217/imt.14.85.

PMID:
25496333
10.

FOLFIRINOX for locally advanced or metastatic pancreatic ductal adenocarcinoma: the Royal Marsden experience.

Moorcraft SY, Khan K, Peckitt C, Watkins D, Rao S, Cunningham D, Chau I.

Clin Colorectal Cancer. 2014 Dec;13(4):232-8. doi: 10.1016/j.clcc.2014.09.005. Epub 2014 Sep 21.

PMID:
25442814
11.

A randomised, open-label phase II trial of afatinib versus cetuximab in patients with metastatic colorectal cancer.

Hickish T, Cassidy J, Propper D, Chau I, Falk S, Ford H, Iveson T, Braun M, Potter V, Macpherson IR, Finnigan H, Lee C, Jones H, Harrison M.

Eur J Cancer. 2014 Dec;50(18):3136-44. doi: 10.1016/j.ejca.2014.08.008. Epub 2014 Oct 28.

PMID:
25441408
12.

Ramucirumab: successfully targeting angiogenesis in gastric cancer.

Javle M, Smyth EC, Chau I.

Clin Cancer Res. 2014 Dec 1;20(23):5875-81. doi: 10.1158/1078-0432.CCR-14-1071. Epub 2014 Oct 3.

PMID:
25281695
13.

Colorectal cancer with liver metastases: neoadjuvant chemotherapy, surgical resection first or palliation alone?

Khan K, Wale A, Brown G, Chau I.

World J Gastroenterol. 2014 Sep 21;20(35):12391-406. doi: 10.3748/wjg.v20.i35.12391.

14.

Adjuvant therapy decisions based on magnetic resonance imaging of extramural venous invasion and other prognostic factors in colorectal cancer.

Chand M, Swift RI, Chau I, Heald RJ, Tekkis PP, Brown G.

Ann R Coll Surg Engl. 2014 Oct;96(7):543-6. doi: 10.1308/003588414X13814021678835.

PMID:
25245736
15.

Guidance on the management of diarrhoea during cancer chemotherapy.

Andreyev J, Ross P, Donnellan C, Lennan E, Leonard P, Waters C, Wedlake L, Bridgewater J, Glynne-Jones R, Allum W, Chau I, Wilson R, Ferry D.

Lancet Oncol. 2014 Sep;15(10):e447-60. doi: 10.1016/S1470-2045(14)70006-3. Review.

PMID:
25186048
16.
17.

Rituximab, Gemcitabine, Cisplatin and Methylprednisolone (R-GEM-P) is an effective regimen in relapsed diffuse large B-cell lymphoma.

Barton S, Hawkes EA, Cunningham D, Peckitt C, Chua S, Wotherspoon A, Attygalle A, Horwich A, Potter M, Ethell M, Dearden C, Gleeson M, Chau I.

Eur J Haematol. 2015 Mar;94(3):219-26. doi: 10.1111/ejh.12416. Epub 2014 Aug 18.

PMID:
25039915
18.

FcγRIIa and FcγRIIIa polymorphisms and cetuximab benefit in the microscopic disease.

Sclafani F, Gonzalez de Castro D, Cunningham D, Hulkki Wilson S, Peckitt C, Capdevila J, Glimelius B, Roselló Keränen S, Wotherspoon A, Brown G, Tait D, Begum R, Thomas J, Oates J, Chau I.

Clin Cancer Res. 2014 Sep 1;20(17):4511-9. doi: 10.1158/1078-0432.CCR-14-0674. Epub 2014 Jul 1.

PMID:
24987061
19.

TP53 mutational status and cetuximab benefit in rectal cancer: 5-year results of the EXPERT-C trial.

Sclafani F, Gonzalez D, Cunningham D, Hulkki Wilson S, Peckitt C, Tabernero J, Glimelius B, Cervantes A, Dewdney A, Wotherspoon A, Brown G, Tait D, Oates J, Chau I.

J Natl Cancer Inst. 2014 Jun 23;106(7). pii: dju121. doi: 10.1093/jnci/dju121. Print 2014 Jul.

PMID:
24957073
20.

Investigational therapies targeting the ErbB family in oesophagogastric cancer.

Moorcraft SY, Chau I.

Expert Opin Investig Drugs. 2014 Oct;23(10):1349-63. doi: 10.1517/13543784.2014.930126. Epub 2014 Jun 20. Review.

PMID:
24949530
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk